Observational studyAntimicrobial resistance and infection control2026
Trends in the prevalence of bloodstream infections in Spanish hospitals (2013-2023).
Observational study in Antimicrobial resistance and infection control, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBloodstream infections (BSI) represent a growing and significant issue due to their associated mortality, morbidity, and economic burden. This study aimed to assess the prevalence of BSI from 2013 to 2023, by type and onset, and to describe patients' characteristics and identified microorganisms.
methodsData from the point prevalence survey on infections and antimicrobial use in Spanish hospitals were analysed. Logistic regression was conducted to identify temporal trends and associations between different factors and hospital-acquired BSI (HA-BSI). Stepwise backward selection with bootstrap resampling was applied for refinement and internal validation.
resultsFrom 2013 to 2023, a total of 578,780 patients were included and 12,968 patients had a BSI. The mean prevalence of BSI was 22.4‰ (HA-BSI: 11.1‰; community-acquired BSI (CA-BSI): 11.3‰). BSI prevalence rose from 18.0‰ in 2013 to 24.3‰ in 2023, corresponding to a significant 3.5% yearly increase in the odds of infection (OR 1.035, 95% CI 1.029-1.040). This upward trend was also observed for HA-BSI and CA-BSI, with significant increases in the odds of 1.1% (OR 1.011, 95% CI 1.004-1.019) and 5.7% (OR 1.057, 95% CI 1.049-1.065), respectively. The multivariate logistic regression model identified CVC use as the strongest factor associated with BSI with an overall aOR of 8.31 (95% CI 7.58-9.12). The most common microorganisms in HA-BSI were Gram-positive cocci (52.4%) while Enterobacterales were more prevalent in CA-BSI (47.5%). Antimicrobial resistance was significantly higher in HA-BSI for methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecalis, third-generation cephalosporin-resistant Escherichia coli, third-generation cephalosporin-resistant and carbapenem-resistant Klebsiella pneumoniae, and Pseudomonas aeruginosa.
conclusionsThe prevalence of BSI in hospitalised patients in Spain is high and has been increasing over the past decade for both HA-BSI and CA-BSI, underscoring the need for continued efforts to reduce BSI rates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.